Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:DCPHOTCMKTS:EMISNASDAQ:PRNBNASDAQ:SPPINASDAQ:ZIOP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCPHDeciphera Pharmaceuticals$14.18-3.0%$15.65$9.90▼$17.73$1.15B0.39523,076 shs527,033 shsEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/APRNBPrincipia Biopharma$100.05$100.05$25.35▼$101.89$3.32B0.86729,676 shsN/ASPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AZIOPZIOPHARM Oncology$1.08$0.77▼$5.95$187.12M1.712.01 million shs2.13 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCPHDeciphera Pharmaceuticals-0.34%-0.68%-4.44%+1.88%+0.69%EMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%PRNBPrincipia Biopharma0.00%0.00%0.00%0.00%0.00%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%+12.45%ZIOPZIOPHARM Oncology0.00%0.00%0.00%0.00%0.00%This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industryMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCPHDeciphera Pharmaceuticals3.7792 of 5 stars3.42.00.03.82.21.70.6EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AZIOPZIOPHARM OncologyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCPHDeciphera Pharmaceuticals2.80Moderate Buy$23.0062.20% UpsideEMISEmisphere TechnologiesN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/ASPPISpectrum Pharmaceuticals2.00HoldN/AN/AZIOPZIOPHARM OncologyN/AN/AN/AN/ACurrent Analyst RatingsLatest SPPI, EMIS, PRNB, ZIOP, and DCPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2024DCPHDeciphera PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$14.00 ➝ $16.002/7/2024DCPHDeciphera PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $23.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCPHDeciphera Pharmaceuticals$163.36M7.01N/AN/A$4.38 per share3.24EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/APRNBPrincipia Biopharma$35.16M94.50N/AN/A$10.95 per share9.14SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87ZIOPZIOPHARM OncologyN/AN/AN/AN/A$0.58 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCPHDeciphera Pharmaceuticals-$194.94M-$2.29N/AN/AN/A-119.33%-49.44%-38.41%5/1/2024 (Estimated)EMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/APRNBPrincipia Biopharma-$53.79M-$2.09N/AN/AN/AN/A-23.08%-21.11%N/ASPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/AZIOPZIOPHARM Oncology-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/ALatest SPPI, EMIS, PRNB, ZIOP, and DCPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/6/2024Q4 2023DCPHDeciphera Pharmaceuticals-$0.58-$0.54+$0.04-$0.54$45.93 million$48.30 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AZIOPZIOPHARM OncologyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCPHDeciphera PharmaceuticalsN/A3.803.59EMISEmisphere TechnologiesN/AN/AN/APRNBPrincipia BiopharmaN/A17.0117.01SPPISpectrum PharmaceuticalsN/A2.712.38ZIOPZIOPHARM Oncology0.183.433.43OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCPHDeciphera Pharmaceuticals70.96%EMISEmisphere TechnologiesN/APRNBPrincipia Biopharma95.54%SPPISpectrum Pharmaceuticals21.67%ZIOPZIOPHARM Oncology51.03%Insider OwnershipCompanyInsider OwnershipDCPHDeciphera Pharmaceuticals4.43%EMISEmisphere Technologies72.90%PRNBPrincipia Biopharma16.01%SPPISpectrum Pharmaceuticals2.70%ZIOPZIOPHARM Oncology5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDCPHDeciphera Pharmaceuticals35580.80 million77.22 millionOptionableEMISEmisphere Technologies6N/AN/ANot OptionablePRNBPrincipia Biopharma6533.21 millionN/ANot OptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableZIOPZIOPHARM Oncology105216.15 million204.91 millionOptionableSPPI, EMIS, PRNB, ZIOP, and DCPH HeadlinesSourceHeadlineChildhood Cancerscuretoday.com - February 17 at 5:57 PMAlx Oncology Holdings (ALXO)investing.com - February 10 at 8:15 PMPediatric Hematology-Oncology Fellowshipbcm.edu - February 5 at 8:39 AMAlaunos Therapeutics: Other Events, Financial Statements And Exhibitscbonds.com - January 31 at 9:44 AMCG Oncology Increuters.com - January 31 at 4:43 AMOncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patientsmedscape.com - December 21 at 3:43 PMImmuno-Oncologyajmc.com - December 19 at 3:21 PMWhy Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?markets.businessinsider.com - December 18 at 8:18 AMExploring Patient-Centered Handoffs in Surgical Oncologymedscape.com - December 10 at 7:36 PMAssociation of Community Cancer Centersajmc.com - October 14 at 2:50 PMOncology News and Researchnews-medical.net - September 19 at 5:53 PMWBSPH 2024 - Oncologynewsweek.com - September 15 at 8:49 PMKris on Oncologymedscape.com - September 6 at 11:16 PMGauging Ziopharm's Chances for Positive Sarcoma Drug Trial Resultsthestreet.com - August 29 at 6:23 AMOncology Cases & Quizzesmedscape.com - August 14 at 6:15 PMZiopharm’s palifosfamide fails in first-line STS…investing.com - June 21 at 12:05 AMWeber on Oncologymedscape.com - June 19 at 2:11 PMA Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanomaascopubs.org - June 17 at 8:43 AMALX Oncology Holdings Inc Ordinary Sharesmorningstar.com - June 15 at 6:54 PMDivision of Pediatric Hematology and Oncologyslu.edu - June 13 at 3:50 PMDivision of Hematology and Medical Oncologyslu.edu - June 13 at 3:50 PMIntratumoral Cancer Therapies Global Market Report 2023finance.yahoo.com - June 9 at 1:32 PMNatural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.comarketwatch.com - May 11 at 9:52 PMVC Identifies 3 Startups That Will Shake Up the Future of Cancer Caremedcitynews.com - May 10 at 1:58 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsDeciphera PharmaceuticalsNASDAQ:DCPHDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.Emisphere TechnologiesOTCMKTS:EMISEmisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Principia BiopharmaNASDAQ:PRNBPrincipia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.Spectrum PharmaceuticalsNASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.ZIOPHARM OncologyNASDAQ:ZIOPZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.